



Itw

I hereby Certify that this Correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on August 12, 2004

Susan L. Eick

Name

Susan L. Eick

Signature

August 12, 2004

Date of Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Egilmez

Filed: December 30, 2003

Serial No. 10/748,003

For: A Method for Inhibiting the Growth of Gastrointestinal Tract Tumors

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicant wishes to make of record the references listed in the attached Form 1449. Legible copies of the references listed are enclosed.


It is believed that no fee is due. However, if that is incorrect, the Examiner is authorized to charge any fee due to Deposit Account No. 08-2442.

Respectfully submitted,

By:

Ranjana Kadle
Ranjana Kadle, Reg. No. 40,041

HODGSON RUSS LLP
One M & T Plaza, Suite 2000
Buffalo, New York 14203-2391
Tel: (716) 848-1628
Dated: August 12, 2004



Please type a plus sign inside this box +

PTO/SB/08B(05/03)

Approved for use through 05/31/2003, OMB 0651-0031

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/748,003
				Filing Date	December 30, 2003
				First Named Inventor	Egilmez
				Group Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	40543.0001

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	CAVALLO et al., <i>Antitumor Efficacy of Adenocarcinoma Cells Engineered to Product Interleukin 12 (IL-12) or Other Cytokines Compared With exogenous IL-12</i> , Journal of the National Cancer Institute (July 16, 1997), Vol. 89, No. 14, pp. 1049-1058	
	2	COLOMBO et al., <i>Immunotherapy I: Cytokine Gene Transfer Strategies</i> , Cancer and Metastasis Reviews (1997) Vol. 16 pp. 421-432	
	3	EGILMEZ et al., <i>In Situ Tumor Vaccination with Interleukin-12-Encapsulated Biodegradable Microspheres: Induction of Tumor Regression and Potent Antitumor Immunity</i> , Cancer Research (July 15, 2000) Vol. 60, pp. 3832-3837	
	4	GILBOA, <i>Immunotherapy of Cancer with Genetically Modified Tumor Vaccines</i> , Seminars in Oncology (February 1996) Vol. 23, No. 1, pp. 101-107	
	5	HILL et al., <i>Cancer Immunotherapy with Interleukin 12 and Granulocyte-Macrophage Colony-Stimulating Factor-Encapsulated Microspheres: Coinduction of Innate and Adaptive Antitumor Immunity and Cure of Disseminated Disease</i> , Cancer Research (December 15, 2002) Vol. 62, pp. 7254-7263	
	6	JANSSEN et al., <i>The Immunological Effects of Interleukin-2 In Vivo</i> , Cancer Immunol. Immunother. (1994) Vol. 39, pp. 207-216	
	7	LEONARD et al., <i>Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12-Associated Toxicity and Interferon-γ Production</i> , Blood (October 1, 1997) Vol. 90, No. 7, pp. 2541-2548	
	8	MINEV et al., <i>Cancer Vaccines: Novel Approaches and New Promise</i> , Pharmacol. Ther. (1999) Vol. 81, No. 2, pp. 121-139	
	9	SOGN, <i>Tumor Immunology: The Glass is Half Full</i> , Immunity (December 1998) Vol. 9, pp. 757-763	
	10	SUN et al., <i>Vaccination with IL-12 Gene-Modified Autologous Melanoma Cells: Preclinical Results and a First Clinical Phase I Study</i> , Gene Therapy (1998) Vol. 5, pp. 481-490	
	11	TÜTING et al., <i>Gene-Based Strategies for the Immunotherapy of Cancer</i> , J. Mol. Med. (1997) Vol. 75, pp. 478-491	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number. ² Applicant is to place a check mark here if English Translation is attached.

Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.